Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.44
-0.0300-0.26%
Post-market: 11.35-0.0900-0.79%18:22 EDT
Volume:548.63K
Turnover:6.31M
Market Cap:872.14M
PE:-4.08
High:11.66
Open:11.54
Low:11.29
Close:11.47
Loading ...

Nurix Therapeutics (NRIX) Receives a Buy from Barclays

TIPRANKS
·
11 Dec 2024

Nurix Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $35

THOMSON REUTERS
·
10 Dec 2024

Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
10 Dec 2024

Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans

TIPRANKS
·
10 Dec 2024

Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham

Dow Jones
·
10 Dec 2024

BRIEF-Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948

Reuters
·
10 Dec 2024

Nurix Therapeutics Inc - Favorable Safety Profile Across All Doses Tested

THOMSON REUTERS
·
10 Dec 2024

Nurix Therapeutics Presents New Positive Data From Phase 1a/1B Clinical Trial of Nx-5948 in Chronic Lymphocytic Leukemia at the 66TH American Society of Hematology Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

Nurix Therapeutics holds a pharmaceutical update conference call

TIPRANKS
·
09 Dec 2024

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
25 Nov 2024

Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe

MT Newswires Live
·
21 Nov 2024

BRIEF-Nurix Therapeutics Receives Prime Designation From The European Medicines Agency For NX-5948

Reuters
·
21 Nov 2024

Nurix Therapeutics announces PRIME designation for NX-5948 from EMA

TIPRANKS
·
21 Nov 2024

Nurix Therapeutics Receives Prime Designation From the European Medicines Agency for Nx-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

THOMSON REUTERS
·
21 Nov 2024

Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024

THOMSON REUTERS
·
17 Nov 2024

Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham

Dow Jones
·
06 Nov 2024

Promising Efficacy and Safety of Nurix Therapeutics’ NX-5948 Justifies Buy Rating

TIPRANKS
·
06 Nov 2024

Cathie Wood's Latest Shake-up: Dumps Palantir And Jack Dorsey's Block Along With Tesla, Buys Amazon And Meta

Benzinga
·
05 Nov 2024

BRIEF-Nurix Therapeutics To Offer And Sell $300 Mln Of Common Stock

Reuters
·
01 Nov 2024

Nurix Therapeutics Inc - Enters Amendment No. 2 to Equity Distribution Agreement

THOMSON REUTERS
·
01 Nov 2024